Skip to content

Join Us
Members Area

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Insulin Resistance & Diabetes

Positive interplay between FFAR4/GPR120, DPP-IV inhibition and GLP-1 in beta cell proliferation and glucose homeostasis in obese high fat fed mice

Owolabi AI, Corbett RC, Flatt PR, McKillop AM. Positive interplay between FFAR4/GPR120, DPP-IV inhibition and GLP-1 in beta cell proliferation and glucose homeostasis in obese high fat fed mice Peptides
Insulin Resistance & Diabetes

Baseline phenotypes with preserved β-cell function and high insulin concentrations have the best improvements in glucose tolerance after weight loss: results from the prospective DEXLIFE and EGIR-RISC studies

Sabatini S, Nolan JJ, O'Donoghue G, Kennedy A, Petrie J, Walker M, O'Gorman DJ, Gastaldelli A. Baseline phenotypes with preserved β-cell function and high insulin concentrations have the best improvements in glucose tolerance after weight loss: results from the prospective DEXLIFE and EGIR-RISC studies Metabolism
Insulin Resistance & Diabetes

A healthful plant-based diet is associated with lower type 2 diabetes risk via improved metabolic state and organ function: A prospective cohort study

Thompson AS, Candussi CJ, Tresserra-Rimbau A, Jennings A, Bondonno NP, Hill C, Sowah SA, Cassidy A, Kühn T. A healthful plant-based diet is associated with lower type 2 diabetes risk via improved metabolic state and organ function: A prospective cohort study Diabetes Metab
Insulin Resistance & Diabetes

Recent advances in peptide-based therapies for obesity and type 2 diabetes

Bailey CJ, Flatt PR, Conlon JM. Recent advances in peptide-based therapies for obesity and type 2 diabetes Peptides
Insulin Resistance & Diabetes

The emergence of obesity in type 1 diabetes

Kueh MTW, Chew NWS, Al-Ozairi E, le Roux CW. The emergence of obesity in type 1 diabetes Int J Obes (Lond)
Insulin Resistance & Diabetes

The double burden: Navigating type 1 diabetes and obesity

Steenackers N, Feldman AN, Mathieu C, Rosen J, Soderberg J, Al-Ozairi E, le Roux CW, Van der Schueren B. The double burden: Navigating type 1 diabetes and obesity Clin Obes
Insulin Resistance & Diabetes

Exposure to gestational diabetes mellitus increases subclinical inflammation mediated in part by obesity

Musumeci A, McElwain CJ, Manna S, McCarthy F, McCarthy C. Exposure to gestational diabetes mellitus increases subclinical inflammation mediated in part by obesity Clin Exp Immunol
Insulin Resistance & Diabetes

Restoration of blood vessel regeneration in the era of combination SGLT2i and GLP-1RA therapy for diabetes and obesity

Terenzi DC, Bakbak E, Teoh H, Krishnaraj A, Puar P, Rotstein OD, Cosentino F, Goldenberg RM, Verma S, Hess DA. Restoration of blood vessel regeneration in the era of combination SGLT2i and GLP-1RA therapy for diabetes and obesity Cardiovasc Res
Insulin Resistance & Diabetes

Obesity Treatments to Improve Type 1 Diabetes (OTID): a randomized controlled trial of the combination of glucagon-like peptide 1 analogues and sodium-glucose cotransporter 2 inhibitors-protocol for Obesity Treatments to Improve Type 1 Diabetes (the OTID trial)

Al-Ozairi E, Narula K, Miras AD, Taghadom E, Samad AE, Al Kandari J, Alyosef A, Mashankar A, Al-Najim W, le Roux CW. Obesity Treatments to Improve Type 1 Diabetes (OTID): a randomized controlled trial of the combination of glucagon-like peptide 1 analogues and sodium-glucose cotransporter 2 inhibitors-protocol for Obesity Treatments to Improve Type 1 Diabetes (the OTID trial) Trials
Insulin Resistance & Diabetes

An update on galanin and spexin and their potential for the treatment of type 2 diabetes and related metabolic disorders

Gallagher DM, O'Harte FPM, Irwin N. An update on galanin and spexin and their potential for the treatment of type 2 diabetes and related metabolic disorders Peptides
Insulin Resistance & Diabetes

Older posts

Newer posts

← Previous Page1 … Page3 Page4 Page5 … Page34 Next →

Search for:

Recent Posts

9th ASOI Annual Conference – Registration now open!
Press Release for World Obesity Day 4th March 2024
ASOI and ICPO response to : Medical Council Communication: “Important medicine shortage information – Ozempic (semaglutide)”
Things to do in Dublin during ECO
ECO 2023 sponsorship update

ASOI

info@asoi.info

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Privacy Policy
Site Map

©2025 ASOI